Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07712094 Cisplatin Gastro-Enteropancreatic Neuroendocrine Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07712094 clinical trial report covering Cisplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07712029 Pucotenlimab Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07712029 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07711418 Rezpegaldesleukin Moderate Atopic Dermatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07711418 clinical trial report covering Rezpegaldesleukin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07710196 N-Acetylcysteine amide Usher Syndromes Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710196 clinical trial report covering N-Acetylcysteine amide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07712692 HPV-16 targeted mRNA vaccine(Novi Technology) Squamous Intraepithelial Lesions of the Cervix Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07712692 clinical trial report covering HPV-16 targeted mRNA vaccine(Novi Technology), Phase 2, endpoints, sponsor, geography, readout timing and developme
Latest Hotspot
8 min read
NCT07710872 Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi) Meningococcal Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710872 clinical trial report covering Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi), Phase 3, endpoints, sponsor, geogra
Latest Hotspot
8 min read
NCT07709767 Retlirafusp alfa stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07709767 clinical trial report covering Retlirafusp alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07710612 ABSK-043 EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710612 clinical trial report covering ABSK-043, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07712380 Respiratory Syncytial Virus Vaccine (GSK) Cardiovascular Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07712380 clinical trial report covering Respiratory Syncytial Virus Vaccine (GSK), Phase 2, endpoints, sponsor, geography, readout timing and development w
Latest Hotspot
8 min read
NCT07710534 Decitabine/Cedazuridine Relapsing acute myeloid leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710534 clinical trial report covering Decitabine/Cedazuridine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07711002 Enzalutamide Hormone-dependent prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07711002 clinical trial report covering Enzalutamide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07711483 Obinutuzumab Large B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07711483 clinical trial report covering Obinutuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.